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ABSTRACT OF THESIS 
ASSOCIATION BETWEEN DISPENSING CHANNEL AND 
CHRONIC OBSTRUCTIVE PULMONARY DISORDER EXACERBATIONS 
AMONG MEDICARE BENEFICIARIES 
Elderly patients with chronic obstructive pulmonary disorder may be at increased risk of 
exacerbation due to physical and cognitive deficits that make proper inhaled medication 
adherence more difficult despite consistent medication access. This retrospective study utilized 
administrative medical and pharmacy claims data to examine the likelihood of having a COPD 
exacerbation requiring acute medical care by means of an emergency room visit or 
hospitalization in elderly patients receiving maintenance COPD medications from mail order and 
retail pharmacies. It was hypothesized that mail order patients would be more likely to experience 
exacerbations despite differences in medication access when compared to retail patients. The 
primary outcome of interest was exacerbation frequency expressed as the incidence density rate, 
and the secondary outcome was the proportion of days covered (PDC).  The incidence rate ratio 
for acute exacerbations was not significantly different for mail order and retail groups, indicating 
patients using mail-order pharmacies were not significantly more likely to experience an 
exacerbation requiring acute medical care. Despite insignificant differences in incidence rates, 
mail order patients had significantly higher adherence rates. 
KEYWORDS: Chronic Obstructive Pulmonary Disorder, Acute Exacerbations, Medicare, 
Adherence, Dispensing Channel 
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Section One: Background 
Introduction 
Chronic obstructive pulmonary disorder (COPD) is an incurable, progressively life threating 
disease that is projected to be the third leading cause of death by 2020. [1] Although the exact 
prevalence is often underestimated, studies have suggested that prevalence of COPD increases in a 
stepwise manner with age. [1-3] Medication adherence, evidenced by a high proportion of days 
covered (PDC), has been associated with fewer respiratory related emergency room visits and 
hospitalizations for COPD patients in general. [4] The complex regimens used to manage COPD 
patients, however, may be more problematic in older adults as physical and cognitive changes make 
proper adherence more difficult despite increased PDC rates. [5]. While several studies have linked 
obtaining maintenance medications through mail order to increased adherence rates for diabetes, 
hypertension, and hyperlipidemia [6, 7] ,few have explored the relationship between the dispensing 
channel and adherence rates or outcomes for individuals with chronic respiratory disorders. [8]  
Chronic Obstructive Pulmonary Disorder in Geriatric Populations 
Burden of Disease      
Chronic Obstructive Pulmonary Disease (COPD) is a life threatening disorder 
characterized by progressive airflow limitation from chronic inflammation and structural changes 
in parenchymal tissues. [9] Estimates of the true burden of COPD are often underreported; 
however, the prevalence is estimated at approximately 14% in patients over 64 years old. [5] As 
the population ages, the prevalence is believed to increase in a stepwise manner. The natural course 
of COPD is marked by recurrent exacerbations associated with decreased lung function, lower 
quality of life, faster disease progression, and increased mortality. [10]  These social implications 
coupled with the financial burden associated with high healthcare utilization have prompted the 
Centers for Disease Control and Prevention (CDC) to list reducing COPD-related emergency room 
visits by 30% and COPD-related hospitalizations by 10% by 2020. [11]   
Complexities of Medical Management 
Adequate medication adherence is a key factor in reducing exacerbation frequency; 
however, medication adherence among patients with COPD is currently suboptimal. [12] A primary 
factor associated with poor adherence is complex medication regimens requiring physical 
coordination for inhaler usage. [13] Some patients are intentionally non-adherent to medications 
and deliberately discontinue therapy. On the other hand, unintentional non-adherence is often 
related to cognitive impairment, language barriers, or physical disabilities. [14] Elderly patients 
with COPD have highlighted difficulties understanding the medication regimen as a major cause 
in therapy lapses. Additional concerns with regard to elderly patients managing their COPD include 
visual and dexterity issues preventing the appropriate use of inhaled devices. [15] These challenges 
may require interventions beyond medication possession to ensure adequate therapy.  
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Implications of Inadequate Intervention 
Currently, COPD interventions follow a reactive pattern in which patient- physician 
interaction is limited to treatment of acute illness such as exacerbations requiring immediate 
medical attention. [16] As a multifactorial, progressive disease, rescue care alone is an inadequate 
approach to improving disease prognosis. [17] While maintenance medications are integral, failure 
to implement patient care models that address factors beyond medication possession is detrimental 
to patient outcomes. Appropriate maintenance pharmacotherapy should be coupled with lifestyle 
modifications such as smoking cessation and increased physical activity to proactively reduce the 
frequency of acute exacerbations and decrease disease progression. Interdisciplinary care teams 
which include primary care providers, nurses, and pharmacists are essential in ensuring continuity 
of care for optimal outcomes. [18] 
Dispensing Channel and Chronic Disorders 
Several studies have linked the use of mail order pharmacies to improved health outcomes 
across several chronic disease states such as diabetes, hypertension, and hyperlipidemia due to 
higher medication adherence rates. [7, 15] These increased adherence rates have been attributable 
to the availability of 90 day supply prescriptions when using mail order. In recent years, many 
prescription drug plans have allowed patients to fill 90-day supply prescription regardless of the 
dispensing channel. [19] A systematic review of recent studies shows mixed results with regards to 
whether the use of a mail order pharmacy improves adherence rates with regards to chronic disease. 
[7] Even though some patients are financially incentivized to use mail order, the ability to obtain 
the same quantity at a local pharmacy may reduce the perceived benefit of mail order use. 
Adherence, however, can be measured in various ways, and is difficult to capture through current 
acceptable methods.
Medication adherence has been evaluated repeatedly by applying measures such as 
medication possession ratio (MPR) and proportion of days covered (PDC) to administrative claims 
data. [20] While MPR directly calculates the sum of days’ supply dispensed over a period, PDC 
considers the medication supply available throughout the period. [21] Both measures reflect a ratio 
that compares a proxy for days of medication compliance in the numerator to an observed period in 
the denominator. [22] Unfortunately, these methods are limited because they do not account for 
personal attributes that lead to non-adherence. More personalized approaches such as direct 
observation and patient surveys are often limited by increased costs. [23] Healthcare providers not 
only have the ability to encouraging patients to be more adherent to medications, but also ensure 
adherence burdens such as regimen comprehension or administration technique are overcome.   
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Section Two: Specific Aims 
Specific Aim and Hypothesis 
Because the medication regimens for elderly COPD patients are highly susceptible to 
adherence problems beyond medication possession, it is critical to assess whether the use of a mail 
order or retail pharmacy influences health outcomes of this patient population. This study aimed to 
evaluate the frequency of respiratory-related hospitalizations and emergency room visits in patients 
filling their COPD maintenance medications at mail order pharmacies compared to patients filling 
these medications at retail pharmacies.  
The specific aims are as follows: 
1. Evaluate the likelihood of having a COPD exacerbation requiring acute medical care by
means of an emergency room visit or hospitalization in elderly patients receiving
maintenance COPD medications from mail order and retail pharmacies
It was hypothesized that Medicare beneficiaries using mail order pharmacies will be more
likely to experience COPD exacerbations requiring hospital care.
2. Measure the adherence rates of elderly patients utilizing mail order and retail pharmacies.
It was hypothesized that there would not be significant difference between adherence rates
among Medicare beneficiaries using different dispensing channels.
The rationale supporting the expressed hypotheses is based upon evidence that medication 
possession alone is not indicative of appropriate administration techniques or adequate compliance, 
especially with regard to inhaled medications. Furthermore, the hypotheses account for the value 
of potential physical interactions with local pharmacy staff in the management of complex 
regimens. 
Significance 
As the population of geriatric COPD patients continues to rise, this study will provide 
additional information for developing health system interventions that improve health outcomes in 
the presence of adequate medication access. By improving health outcomes and proper medication 
adherence, we not only reduce the morbidity and mortality associated with COPD, but also reduce 
overall healthcare spending and utilization linked to preventable events. 
Approach 
A randomized trial to evaluate the effect of dispensing channel on health outcomes would 
need to mimic plan benefit designs with mandatory home delivery or retail services. Mandatory 
mail order has been shown to negatively influence adherence rates and thusly therapy effectiveness. 
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[24] A design in which the action of randomization can potentially influence the outcome due to
human preference would yield inherently biased results; therefore, an observational study
controlling for known confounders while allowing patient preference would be more desirable.
Previous studies have investigated the association between medication adherence and dispensing
channel across several chronic disease states and medication classes. [7] Few of these studies have
focused on Medicare eligible populations and even fewer have examined the impact on COPD.
Because the results of these studies have generally concluded there is little difference in adherence
rates when using mail order over retail pharmacies, it is important to evaluate any variations in
health outcomes and quality of care for each dispensing channel. Pharmacists are uniquely trained
to assist ambulatory patients in the management of chronic disorders, including COPD. With
frequent physical pharmacist interaction, patients can be assessed for regimen comprehension as
well as administration technique. This is a benefit not available through mail order pharmacies.
Section Three: Methodology 
Research Design 
Data Source and Overall Approach 
This retrospective, observational study focused on retired beneficiaries enrolled between 
January 1, 2007 and January 1, 2012 in a Medicare Advantage plan. De-identified and internally 
linked paid claims with respect to prescriptions, inpatient services, outpatient services, and person-
level enrollment information was obtained directly from one of the nation’s largest claims 
databases, the Humana Comprehensive Health Insights Outcomes Data. Data extraction was 
completed through consultation with a trained data analyst. Due to the de-identified nature of the 
data, informed consent was not required from study participants. 
A new-user design approach with an active comparator was applied in order to capture the 
impact of the dispensing channel on the outcomes. While utilizing new-users may limit the 
observation of study participants with more advanced disease, this approach reducing the challenge 
of confounding by indication. The active comparator was necessary for the purposes of this study 
because of the nature of the specified exposure criteria.  
Inclusion/Exclusion Criteria 
The sample was restricted to patients aged 65 years and older who were diagnosed with 
COPD as defined by the following: chronic bronchitis (ICD-9 codes 490-491), emphysema (ICD-
9 code 492), bronchiectasis (ICD-9 code 494), or chronic airway obstruction (ICD-9 code 496). 
Inclusion was limited to patients who were continuously enrolled in a Medicare plan with both 
medical and pharmacy benefits for at least eight months between January 1, 2007 and January 1, 
2012. A minimum eight month enrollment period was required in order to observe both a six month 
preliminary period prior to diagnosis and the subsequent filling of two qualifying inhaled 
prescriptions. Federally approved inhaled prescription medication for the chronic management of 
COPD include long-acting beta agonists (LABA), inhaled corticosteroids (ICS), inhaled anti-
muscarinics, or a combination product containing these medication classes throughout the study 
period (see Appendix A for a complete list of qualifying inhaled medications).  
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 Prevalent users, defined as patients with prescription claims for any of the previously 
specified inhaled therapies within the 6 months preceding the first coded COPD diagnosis during 
the study period, were excluded. Patients who did not obtain a medication refill within 90 days of 
expected medication depletion from the initial fill were excluded from the study. Additionally, 
patients without available diagnostic data were excluded from the study. A total of 28,657 Medicare 
patients were identified as having COPD. Of this cohort, 4,316 patients met the inclusion criteria. 
(Figure 3.1) The control population for this study consisted of 3,802 retail pharmacy patients while 
the intervention arm consisted of 514 mail order patients. There were 512 patients in each treatment 
arm following propensity score matching.   
Figure 3.1 Flow Chart of Sample Selection 
Medicare beneficiaries aged 65 using 
inhaled medications (N=28,657) 
Patients with at least 2 COPD related 
prescription fills (N=17,355)
Patients assesed for outcomes data 
(N= 9,533)
Cohort before matching 
(N=4,316)
1:1 Propensity Matched Cohort 
(N=1028)
Retail (N=512)Mail order (N=512)
Unable to identify a macth (N=2)
Mail Order (N=514) Retail (N=3,802)
Missing diagnostic data (N=5,217)
Greater than 90 days gap in therapy
(N= 7,822)
Excluded patient with less than 2 
prescription fills  (N=11,302) 
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Study Period 
The study period consisted of three unique time-frames or points: a pre-index period, index 
date, and follow-up. (Figure 3.2) The COPD index date was defined as the first prescription claim 
for a maintenance COPD inhaler following an initial study inclusion diagnosis. A 6-month pre-
index lookback was performed to ensure only new-users proceeded to follow-up as well as gather 
prior medical history. Baseline characteristics such as age, race, and geographical region were 
assessed as of the COPD index date.  The dispensing channel of the first refill or dispensing of the 
second prescription for a maintenance medication determined participant classification as a mail 
order or retail users and study follow-up began from that point. Follow-up continued from 
assignment through the earliest of 15 months, discontinuation of all maintenance COPD 
medications, or termination of either medical or prescription benefits. (Figure 2) Because the 
primary aim did not focus on comparing efficacy between drug classes, individuals utilizing 
multiple inhalers concurrently were evaluated as a single observation. Furthermore, changes 
between therapeutic classes of medications within this period did not constitute discontinuation of 
therapy. 
Figure 3.2 Flow Chart of Study Design 
Exposures 
The primary exposure was the dispensing channel, mail order or retail pharmacy, for which 
the patient filled his or her maintenance COPD medications. Pharmacy type was identifiable 
through a binary mail order indicator featured in the claims database. Because it is common for 
patients to start new medications at their local pharmacies and switch to mail order once tolerated, 
dispensing channel use was defined at the second prescription for a COPD maintenance medication. 
A sensitivity analysis (Appendix B) to assess the appropriateness of this exposure definition was 
performed by classifying dispensing channel based on initial maintenance COPD medication. The 
analysis did not show statistically significant differences in classification and supported the 
decision to capture dispensing channel at the first refill. 
Initial COPD 
Prescription 
Mail 
Order 
Retail 
Follow-up 
Study end: 
The earliest of 15 
months, 
discontinuation of 
therapy, or termination 
of coverage 
No COPD medication use/ 
est. baseline medical history 
6 months 
Index 
 (First Refill) 
Pre-Index 
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Outcomes 
The primary outcome of interest was COPD-related exacerbations requiring acute medical 
care by means of an emergency room (ER) visit, non-routine outpatient visit, or hospitalization. 
Medical visits and hospitalizations were deemed COPD-related through medical claims reflecting 
COPD exacerbation diagnosis (ICD-9 CM code 491.21, 491.22, 492.0, 494.10) in the primary 
diagnostic position. A list of COPD related ICD-9 codes presented in Table 3.1. Exacerbation dates 
and medical setting were also obtained for each event. Medical treatments were only considered 
events if they occurred after the follow-up began in order to reduce the impact of immortal time 
bias. Patients with an exacerbation coded in multiple medical locations were observed as having a 
single exacerbation for analysis purposes.  
Secondary outcomes included frequency of exacerbation by medical setting and COPD 
medication adherence during the study. The measure of adherence chosen was proportion of days 
covered (PDC).  
Table 3.1  COPD related ICD-9 diagnostic codes 
Diagnostic Codes Description 
490.00 Bronchitis, not specified as acute or chronic 
491.00 Simple chronic bronchitis 
491.10 Mucopurulent chronic bronchitis 
491.20 Obstructive chronic bronchitis without exacerbation 
491.21 Obstructive chronic bronchitis with (acute) exacerbation 
491.22 Obstructive chronic bronchitis with acute bronchitis 
492.00 Emphysematous bleb 
492.80 Other emphysema 
494.00 Bronchiectasis without acute exacerbation 
494.10 Bronchiectasis with acute exacerbation 
496.00 Chronic airway obstruction, not elsewhere classified 
Statistical Analysis 
Baseline Comparisons of Treatment Groups 
Summary statistics were used to describe each cohort. Continuous measures were 
described using means and standard deviations while categorical variables were described using 
percentages. Continuous and categorical variables were also compared between each dispensing 
channel using standard t-tests and chi-square test, respectively with standardized differences to 
assess similarities of each dispensing arm. 
 Abbreviations: ICD-9, International Statistical Classification of Diseases and Related Health Problems, Version 9 
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Estimating the Propensity Score 
In efforts to reduce selection bias, a propensity score was estimated using nine variables: 
age, gender, geographical region, race, history of diabetes mellitus, history of heart failure, smoking 
status, quantity of pre-index prescription claims, pre-index medical expenses [25-27]. A directed 
acyclic graph was compiled to determine the minimum sufficient variable set for analyzing the 
association between the specified exposure and primary outcome. (Figure 3.3) These variables were 
chosen due to their likelihood of influencing the outcomes of interest or a patient’s decision to 
choose mail or retail pharmacy to fill maintenance medications. A logistic regression model, which 
regressed dispensing channel (mail order vs retail pharmacy) on the aforementioned baseline 
characteristics to estimate the propensity score [28-30].  
Figure 3.3 Directed Acyclic Graph 
Matching on the Propensity Score 
Mail order and retail patients were matched 1:1 on the propensity score using a radius 
method optimized for the closeness of the propensity scores. [28] There were significantly more 
control (retail) patients than were intervention (mail order) patients. The matching process 
generated matches with absolute differences between propensity scores no greater than 0.02. 
Baseline characteristics were then compared between the matched and unmatched patients using 
means and standard deviations for continuous variables and counts and percentages for categorical 
variables. In order to check the balance of the propensity score estimation, standardized differences 
and p-values were used to quantify the difference between dispensing channels.   
Estimating Effect 
An intention-to-treat analysis as of the second prescription fill was used. Each study 
participant was followed from dispensing arm classification to the study end or medication 
discontinuation regardless of whether he or she continued to refill medications at the original 
pharmacy type.  
All outcomes were analyzed in both the overall and propensity score matched cohorts. The 
primary outcome of interest was the frequency of acute COPD exacerbations during the observed 
study period, expressed as incidence rates. Incidence rates were estimated with the dependent 
variable, count of events, and an offset variable of total time the patients were exposed to an inhaled 
maintenance medication filled through one of the dispensing channels. An incidence rate ratio 
(IRR) and 95% confidence interval (CI) was then estimated by Poisson regression. As a secondary 
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outcome, incidence rates by each of three exacerbation settings; outpatient, emergency room, and 
hospital admittance, were compared in the same manner as the primary outcome of interest. 
Additionally, adherence rates, reported as PDC, were calculated for all patients with at least two 
consecutive fills following dispensing channel assignment. The PDC algorithm truncated fill dates 
occurring outside the observation window and adjusted fill dates to reflect early refills during the 
study period. The PDC means were compared using a two-sample t-test and paired t-test for the 
unmatched and propensity score matched cohorts, respectively. The percentage of patients meeting 
adequate adherence, defined as a PDC greater than or equal to 0.8, were also reported. These 
measures were compared using chi-square tests. All analysis were performed using SAS software 
version 9.4.   
Section Four: Results 
Overall Sample Description 
The study sample consisted of 4,316 participants, of whom 514 used a mail order pharmacy 
and 3,802 used a retail pharmacy. The baseline characteristics of retail and mail order patients are 
described in Table 4.1. Prior to propensity score matching, patients using mail order pharmacies 
tended to have fewer unique prescription claims and lower medical spend during the pre-index 
period (p < 0.001). Retail patients were more likely to reside in the southern region (p<0.001) while 
mail order patients were more likely to reside in western and mid-western regions (p =0.003 and 
p= 0.02, respectively). All other measured covariates were similar between dispensing channels.  
Table 4.1 Baseline Characteristics of Study Sample 
Variable Retail 
(N=3802) 
Mail Order 
(N= 514) 
Overall Sample 
(N= 4,316) 
SD of the 
Mean/Median 
(%) 
p-
value 
Demographic Characteristics 
Age 73.92 ± 7.64 73.28 ± 7.45 73.84 ± 7.62 -8.43 0.08 
Male 1823 (47.95) 235 (45.72) 2058 (47.68) -4.46 0.34 
White 3381 (88.93) 460 (89.49) 3841 (88.99) 1.83 0.70 
Region 
Midwest 
Northeast 
South 
West 
1047 (27.54) 
141 (3.71) 
2210 (58.13) 
404 (10.63) 
166 (32.30) 
17(3.31) 
251 (48.83) 
80 (15.56) 
1213 (28.10) 
158 (3.66) 
2461 (57.02) 
484 (11.21) 
10.40 
-2.18
-18.71
14.67
0.02 
0.65 
<0.001 
0.003 
Contributing Comorbidities 
Diabetes 1026 (26.99) 138 (26.85) 1164 (26.97) 0.31 0.95 
Heart Failure 814 (21.41) 102 (19.84) 916 (21.22) -3.87 0.42 
Smoker 372 (9.78) 42 (8.17) 414 (9.59) -5.64 0.22 
Indicators of Prior Health Status 
Prior Monthly Medical 
Expenses ($), 
median(IQR) 
3,503.52 
(10,721) 
1,751.88 
(4,430) 
3,211.30 
(9,848) 
6.85 <0.001 
Prior Monthly  
Prescription Claims 
median(IQR) 
8.67 
(13.6) 
5.92 
(7.52) 
8.16 
(12.93) 
1.35 <0.001 
Note. Continuous variables are presented as means ±standard deviation; dichotomous variables are presented as N (%) 
 Indicators of Prior Health expressed as medians and IQR 
Abbreviation: SD, Standardized Differences; IQR, interquartile range 
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Propensity score matching  
The 1:1 radius matching technique, which was maximized on closeness of the propensity 
score, generated matches for 513 mail order patients to retail patients within an absolute difference 
of less than or equal to 0.02 of the propensity score. Only one mail order patient was unable to be 
successfully matched to a retail patient with a similar propensity score. The baseline characteristics 
of each dispensing arm in the matched cohort are described in Table 4.2. Post-matching, all 
standardized differences were less than 10%. The only covariates that differed by more than 5% 
were related to geographic region (West and Midwest) and monthly medical expenses during the 
pre-index period, exceeded differences of 5 percent.  
Table 4.2 Baseline Characteristics of Mail Order and Retail Participants in the Propensity Score 
Matched Sample 
Variable Retail 
(N=512) 
Mail order 
(N=512) 
SD of the 
Mean/median 
(%) 
Variance 
Ratio 
p-value
Demographic Characteristics 
Age 73.50 ± 7.03 73.28 ± 7.45 -2.98 1.12 0.63 
Male 234 (45.70) 235 (45.72) 0.03 1.00 0.99 
White 456 (89.06) 460 (89.49) 1.39 1.04 0.82 
Region 
  Midwest 
Northeast 
South 
West 
178 (34.77) 
24 (4.69) 
240 (46.88) 
70 (13.67) 
166 (32.30) 
17 (3.31) 
251 (48.83) 
80 (15.56) 
-5.23
-7.04
3.92
5.35
1.04 
1.40 
1.00 
1.11 
0.40 
0.26 
0.53 
0.39 
Contributing Comorbidities 
Diabetes 130 (25.39) 138 (26.85) 3.32 1.04 0.60 
Heart Failure 107 (20.90) 102 (19.84) -2.61 1.04 0.68 
Smoker 36 (7.03) 42 (8.17) 4.30 1.15 0.50 
Indicators of Prior Health Status 
Prior Monthly 
Medical Spend ($) 
2,091.92 
(6,737) 
1,751.88 
 (4,430) 
7.09 1.19 0.17 
Prior Monthly  
Prescription Claims 
median(IQR) 
5.60 
(7.20) 
5.92 
(7.52) 
1.47 1.04 0.06 
Note. Continuous variables are presented as means ±standard deviation; dichotomous variables are presented as N (%) 
Indicators of Prior Health expressed as medians and IQR 
Abbreviation: SD, Standardized Differences; IQR, interquartile range 
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Effect on acute exacerbations 
Prior to matching, retail pharmacy patients had a higher incidence rate of an acute 
exacerbation when compared to patients using mail order pharmacies (2.41 per 10 person years vs. 
2.07 per 10 person years). The difference in rates, however, was not found to be statistically 
significant (IRR 0.86; 95% CI, 0.63- 1.17; Table 4.3). Retail patients also had higher incidence 
rates for exacerbations treated in an emergency room setting; however, this difference was not 
found to be significant. The rates were the same for both outpatient and hospital settings prior to 
matching. 
Table 4.3 Event rates of acute exacerbation in a cohort of COPD patients using retail and mail 
order pharmacies 
Before Propensity Score 
Matching 
Retail (N=3802) Mail Order (N=514) 
IRR (95% CI) Event 
, (n) 
Person-
years 
IR/ 10 
PY 
Event 
(n) 
Person-
year 
IR/ 10-
PY 
Acute Exacerbation 732 3,035.19 2.41 84 404.28 2.07 0.86 (0.63- 1.17) 
Outpatient 441 3,035.19 1.45 52 404.28 1.45 0.88 (0.64- 1.23) 
Emergency 118 3,035.19 0.39 9 404.28 0.22 0.57  (0.27- 1.20) 
Hospitalization 173 3,035.19 0.57 23 404.28 0.57 1.00 (0.61-1.62) 
Office Visit, Unspecified 3783 3,035.19 12.46 450 404.28 11.13 0.89  (0.80- 0.99) 
Abbreviations: PY, person-years; IR, incidence rate; IRR, Incidence Rate Ratio; CI, confidence interval 
Overall, results following matching continued to show slightly lower incidence rates for 
mail order patients, regardless of treatment setting. Acute exacerbation incidence rates were 2.44 
per 10 person years and 2.07 per 10 person years for retail and mail order patients, respectively. 
The difference in these rates, however, remained statistically insignificant (IRR 0.85; 95% CI, 0.59- 
1.23; Table 4.4).  
Table 4.4 Event rates of acute exacerbation and office visits in a matched cohort of COPD 
patients using retail and mail order pharmacies 
After Propensity Score 
Matching 
Retail (N=512) Mail Order (N=512) 
IRR (95% CI) Event 
, (n) 
Person-
years 
IR/ 10 
PY 
Event 
(n) 
Person-
year 
IR/ 10-
PY 
Acute Exacerbation 84 343.62 2.44 84 404.28 2.07 0.85   (0.59-1.23) 
Outpatient 53 343.62 1.54 52 404.28 1.45 0.83 (0.54- 1.27) 
Emergency 10 343.62 0.29 9 404.28 0.22 0.77  (0.31- 1.91) 
Hospitalization 21 343.62 0.61 23 404.28 0.57 0.93 (0.49- 1.75) 
Office Visit, Unspecified 430 343.62 12.51 450 404.28 11.13 0.89 (0.78- 1.02) 
Abbreviations: PY, person-years; IR, incidence rate; IRR, Incidence Rate Ratio; CI, confidence interval 
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Effect on adherence rates 
The adherence rates, defined as proportion of days covered (PDC), were significantly lower 
for retail patients (0.66 ± 0.24; 95% CI 0.65-0.67) when compared to mail order patients (0.79 ± 
0.20; 95% CI, 0.77-0.81) in the overall sample population (p <0.001, Table 5). While the average 
PDC in mail order patient was identical in the matched cohort, the average retail PDC was slightly 
lower at 0.63. The difference in mean adherence rates continued to be significantly different in the 
matched cohort (p< 0.001, Table 6). Neither mail order or retail pharmacy patients had and overall 
adherence rate indicative of adequate adherence (pdc ≥ 0.8), but there were nearly twice as many 
mail order patients that were adequately adherent (54.81%) when compared to retail patients in the 
overall sample and matched cohort (29.77% and 54.81%, respectively).  
Table 4.5 Inhaled maintenance medication adherence rates in COPD patients using mail order and 
retail pharmacies 
Retail Mail Order p-value
Before Propensity Score Matching 
PDC 
N=3389 
0.66 ± 0.24 
N= 416 
0.78 ± 0.20 <0.001 
Adherent† (%) 1132 (29.77) 228 (54.81) <0.001 
After Propensity Score Matching 
PDC 
N=410 
0.63 ± 0.24 
N= 416 
0.78 ± 0.20 <0.001 
Adherent† (%) 117 (28.54) 228 (54.81) <0.001 
Abbreviations: PDC, proportion of days covered 
†Adherence, PDC greater than or equal to 0.80 
Section Five: Discussion and Conclusions 
Discussion 
This population based study examining the association between dispensing channel and 
acute COPD exacerbations among Medicare patients did not yield statistically significant findings; 
however, there are notable trends within this population that should be examined with further 
studies. Pharmacy benefit managers have promoted mail order use as a means to increase 
medication access and therefore improve adherence. Medication adherence may be defined as a 
PDC greater than or equal to 0.80. By this definition, neither retail nor mail order elderly COPD 
patients achieved adequate adherence. Patients using mail order pharmacies not only yielded higher 
PDC rates, but also had a significantly greater percentage of patients achieve adequate adherence 
per the definition. 
As adherence to medication increases, outcomes should improve as long as the medication 
is an efficacious treatment option. Despite superior adherence rates in mail order patients, there 
were insignificant differences in incidence rates of exacerbation between the two groups. The 
findings suggest that apparent medication access alone is not indicative of appropriate medication 
adherence, especially when administration techniques are critical to therapy efficacy. Because 
COPD is such a complex chronic condition, there may be an increased need to implement disease 
management programs focusing on factors beyond medication access that contribute to decreased 
exacerbation frequency and improved outcomes. These results could lead one to believe that a large 
portion of medication dispensed to mail order recipients is wasted to either voluntary non-
adherence or inappropriate medication administration.  
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A major strength of this study was national representation of a large number of Medicare 
beneficiaries of varying ages. The sample is not only representative of an understudied population 
in which COPD is a highly prevalent disease, but also accounts for demographic traits that are 
applicable to disease progression. Furthermore, propensity score matching helped reduce the effects 
of confounding variables. There is limited data available that highlights which factors make a 
patient more or less likely to fill medications at a retail or mail order pharmacy. The low predictive 
value of the propensity score can be explained by the fact that patient preference, a key driver in 
pharmacy choice, is not measureable through administrative claims data.  
It was hypothesized that mail order patients would be more likely to experience acute 
exacerbations. The primary rationale behind the hypothesis took into account the potential for direct 
interaction with pharmacy personnel for retail patients. Unfortunately, this was not a measurable 
attribute utilizing claims data. As prescription volume increases, retail pharmacists and support 
staff have less time to actively counsel and assess appropriate medication use. Taking advantage of 
opportunities available through retail pharmacies to encourage medication regimen compliance 
could help reduce exacerbations, especially in geriatric populations requiring additional assistance. 
Currently, the lack of difference in exacerbation rates coupled with increased adherence rates 
among mail order patients contradicts the general notion that medication adherence improves 
patient outcomes.  
One possible explanation of the failure of this study to identify a significant difference in 
exacerbation rates is related to potentially observing patients with less severe disease through a 
new-user design. While some patients may only begin treatment after the disease has significantly 
progressed, it is possible that the participants in this study were identified the earlier stages of 
disease. Balcells et al. demonstrated that one-third of newly diagnosed COPD were identified as a 
result of a COPD exacerbation requiring acute care. [31] These same patients also had a decreased 
risk of re-hospitalization when compared to patients with an established COPD diagnosis.   A 
relatively healthy population is supported by the low incidence rate ratio of exacerbations compared 
to reported averages ranging from low as 0.09 to 2.4 per patient per year. [32] Additional studies 
that identify patients of varying COPD stages may show more difference between the two 
dispensing channels. Additionally, neither mail order nor retail patients in this population achieved 
adequate adherence overall. While the difference in adherence may be statistically significant, this 
difference could potentially not translate to clinical significance if the additional access is not 
sufficient to prevent additional exacerbations.  
It was also hypothesized that there would be no significant difference in the adherence rates 
between mail order and retail patients. The most prominent explanation for this difference is the 
financial incentives associated with mail order use.[33] While 90-days supply prescriptions can be 
filled at both retail and mail order pharmacies, medication affordability makes filling medications 
through mail order more economically feasible. The majority of the inhaled maintenance 
medications are still branded medications and could cost significantly more at a retail pharmacy, 
thusly reducing the ability of Medicare patients using this dispensing channel to refill their 
medications. 
There were several limitations to this study. Firstly, there was potential opportunity for 
misclassification of dispensing arm due to the intention to treat analysis. It is common for patients 
starting a new medication to begin the initial prescription at the local pharmacy, especially when 
the timing of therapy initial is critical. While most patients tended to fill their maintenance 
medications through a single dispensing channel (mail order or retail pharmacy), there was a 
possibility that patients could alternate between the two as frequently as desired throughout the 
study period. A dispensing sequence sensitivity analysis showed that there was little difference in 
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classification for patients when assigned at the second prescription when compared with the initial 
prescription (Appendix B).  
Secondly, several outpatient events were nonspecific as acute or chronic in nature as 
defined by the ICD-9 code selected from the provider. Issues related to ambiguous coding could be 
reduced by including prescription data that also captured antibiotics and/or steroid prescriptions 
filled on the same day as the medical treatment date of COPD related event. Outpatient visits with 
non-specific codes were deemed as routine visits for the purpose of this study. Although not an 
official outcome of this study, post-hoc analysis showed no significant difference in the rates of 
office visits (unspecified as acute or an exacerbation) between groups in the matched cohort. 
Without additional data, it is unclear whether the specificity of the outcome definition significantly 
influenced the study results.  
Lastly, current adherence measures through administrative claims are a proxy for actual 
adherence and cannot take into account a patient’s true actions. This study was unable to distinguish 
patients who requested medication refills from patients taking advantage of automatic refill 
programs. It is plausible to consider mail order patients increased adherence rates were attributable 
to automatic refill programs rather than actual medication adherence. While automatic refill 
programs and patient reminder systems are also prevalent at local pharmacies, a primary difference 
in the application of these types of programs is the need for retail patients to visit a brick-and-
mortar pharmacy to receive medications that may have been automatically refilled.  The PDC 
algorithm used to estimate adherence reduces the impact of automatic refill programs in either arm 
by adjusting fill dates when overlap occurs. 
Conclusion 
There is no significant difference in exacerbation frequency among Medicare beneficiaries 
using mail order pharmacies when compared to retail pharmacies. Increased medication adherence 
rates have been repeatedly associated with both mail order pharmacies and fewer exacerbations in 
patients with COPD; however, limitations of current adherence measures, unfortunately, make 
examining this association difficult.  Further studies are needed to examine the impact of direct 
patient interaction in a retail environment as compared to self-management with a mail order 
pharmacy.  
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Appendices 
Appendix A 
Table A1 Federal Drug Administration Approved Inhaled Maintenance COPD Medication 
between 2007-2011 
Brand Generic Inhaler 
Type 
Usual Adult Dosage Product NDC 
(USA) 
Corticosteroids 
Alvesco® ciclesonide MDI 80-320 mcg inhaled
BID
63402-0711 
63402-0712 
54868-5989 
54868-5990 
Asmanex® 
Twisthaler 
mometasone furoate DPI 220-440 mcg inhaled
QD or BID
00085-1341 
00085-1461 
Flovent® Diskus fluticasone propionate DPI 100-500 mcg inhaled
BID
00173-0600 
00173-0601 
00173-0602 
Flovent® HFA fluticasone propionate MDI 88-440 mcg inhaled
BID
00173-0718 
00173-0719 
Pulmicort 
Flexhaler® 
budesonide inhalation DPI 360-720 mcg inhaled
BID
00186-0916 
00186-0917 
21695-0291 
54868-5844 
QVAR beclomethasone 
dipropionate 
MDI 40-320 mcg inhaled
BID
59310-0202 
59310-0204 
16590-0860 
50090-1342 
54868-5857 
54868-5858 
Long Acting Beta Agonists (LABA) 
Serevent® Diskus salmeterol xinofate DPI 50 mcg inhaled BID 00173-0520 
00173-0521 
Foradil ® Aerolizer formoterol fumurate DPI 12 mcg inhaled BID 00085-1401 
00085-1402 
Corticosteroid/ LABA combination 
Advair® Diskus fluticasone propionate/ 
salmeterol 
DPI 1 inhalation BID 00173-0695 
00173-0696 
00173-0697 
Advair® HFA fluticasone propionate/ 
salmeterol 
MDI 2 inhalations BID 00173-0715  
00173-0716 
00173-0717 
Dulera® mometasone furoate/ 
formoterol fumarate 
dihydrate 
MDI 2 inhalations 
BID 
08546-1001 
08572-0601 
Symbicort® Budesonide/ formoterol 
fumarate Dihydrate 
MDI 2 inhalations 
BID 
18603-7020 
18603-7220 
Muscarinics 
Spiriva Handihaler® tiotropium bromide DPI 18 mcg inhaled QD 59700-7541 
Abbreviations: NDC, national drug code; HFA, hydrofluoroalkane; DPI, dry powder inhaler; MDI, metered-dose inhaler; QD, 
once daily; BID, twice daily 
References[34]  
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Appendix B 
Because the exposure, dispensing channel, was highly dependent upon patient preference, it was 
important to identify the best method of classifying the exposure arm. An intention-to-treat 
analysis as of the second prescription was utilized in the study. The robustness of this 
classification strategy was assessed with a sensitivity analysis. Table B1 compares the dispensing 
sequence of all patients with qualifying COPD prescriptions when analysis was performed from 
either the initial prescription or the second prescription. The intention-to-treat analysis yielded 
accurate classification for approximately 90 percent of all participants through the study 
observation period regardless of whether the dispensing channel was established at the initial 
prescription or the second prescription. Figure B1 demonstrates the percentage of patients who 
remained in the determined dispensing channel throughout the study in both the overall and 
matched cohorts.  
Table B1 Fill Sequence Comparison in All COPD Patients 
Initial Prescription (n=28,075) Second Prescription 
(n= 17,355) 
Fill Sequence of Dispensing Channel 
Switch 
N % N % 
No Switch 25,314 90.17 15,494 89.28 
At 2nd Observation 1155 4.11 738 4.25 
After 2nd Observation 1606 5.72 1123 6.47 
Figure B1: Intention-to-treat Classification Accuracy in Study Population 
Abbreviations: Rx, prescription; PS, propensity score 
There are two reasons why it was desirable to classify patients as of the second prescription fill. 
The first reason is that it is common for patients beginning a new prescription to begin at the local 
pharmacy and transition to a mail order pharmacy once they are stabilized on the medication. 
Secondly, classifying exposure as of the second fill reduces the impact of immortal time bias on 
treatment outcomes. The primary outcome of interest, exacerbations, is closely related to 
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medication adherence. There is a portion of time between the first and second fill where we can 
neither attribute an exacerbation to the exposure of filling a medication at a particular dispensing 
channel nor estimate medication adherence. Had analysis began at the initial prescription, the 
exacerbation rate may have been overestimated. The sensitivity analysis demonstrates there was 
minimal difference between classifying patients as of the second prescription and the initial 
prescription. 
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